A Case of Organizing Pneumonia (OP) Associated with Pembrolizumab
Open Access
- 22 May 2016
- journal article
- Published by Aboutscience Srl in Drug Target Insights
- Vol. 10 (1)
Abstract
Until recently, chemotherapy for metastatic melanoma had disappointing results. The identification of immune checkpoints such as CTLA-4 and PD-1/PD-L1 has led to the development of an array of monoclonal antibodies (Mabs). These immunologic approaches against tumoral cells come with a novel kind of side effects that the clinician needs to be familiarized with. Herein, we report for the first time a case of organizing pneumonia, based on imaging and cytological analyses of bronchoalveolar lavage, possibly associated with the use of pembrolizumab, an anti-PD-1 Mab recently approved for the treatment of metastatic melanoma.Keywords
This publication has 15 references indexed in Scilit:
- Organizing Pneumonia Induced by Nivolumab in a Patient with Metastatic MelanomaJournal of Thoracic Oncology, 2016
- Anti–PD-1–Related Pneumonitis during Cancer ImmunotherapyNew England Journal of Medicine, 2015
- Pembrolizumab versus Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2015
- Immune Checkpoint Inhibitors in Melanoma Provide the Cornerstones for Curative TherapiesSeminars in Oncology, 2015
- Durable benefit and the potential for long-term survival with immunotherapy in advanced melanomaCancer Treatment Reviews, 2014
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in MelanomaNew England Journal of Medicine, 2013
- PD-1 is a novel regulator of human B-cell activationInternational Immunology, 2012
- Role of PD-1 in Regulating T-Cell Immunity2010
- Rituximab: Mechanism of ActionSeminars in Hematology, 2010
- PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsisProceedings of the National Academy of Sciences, 2009